Chicago Capital Management’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
Other funds holding ESPR
Chicago Capital Management's ESPR Position: Q3 2026 in Review
Chicago Capital Management sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 830,935 shares — an estimated $2.61M sold.
Chicago Capital Management first reported a position in ESPR in Q2 2026 and held it in 1 quarter. The position peaked at $2.61M in Q2 2026. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.
- Chicago Capital Management reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
- Chicago Capital Management sold 830,935 Esperion Therapeutics shares in Q3 2026, an estimated $2.61M.
- Chicago Capital Management first reported a position in Esperion Therapeutics in Q2 2026 and held it in 1 quarter.
- Chicago Capital Management's Esperion Therapeutics position peaked at $2.61M in Q2 2026.
- 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.
Based on Chicago Capital Management's 13F filing for Q3 2026, filed 21 Oct 2026.